# Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

> **NCT04285827** · PHASE1 · COMPLETED · sponsor: **CSL Behring** · enrollment: 28 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **BIOLOGICAL:** CSL889

## Key facts

- **NCT ID:** NCT04285827
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-20
- **Primary completion:** 2023-07-24
- **Final completion:** 2023-07-24
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04285827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04285827, "Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04285827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*